化疗药物联合过氧化物酶体增殖物激活受体(PPAR)的配体能够协同抑制肺细胞癌及卵巢癌细胞。
Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.
例如，后代身上出现的一种称为过氧化物酶体增殖物激活型受体 (Ppara)的基因对调节胆固醇和脂类在肝脏中进行转换起着至关重要的作用。
One gene that changed in offspring, for example — known as Ppara — is essential in cholesterol management and the liver's role in converting lipids.
新型磷结合剂、维生素D类似物及钙敏感受体激活剂等现已陆续进入临床，并取得良好疗效。
The therapeutic effects of new type phosphate binder, vitamin D analogue and calcimimetic compound have been evidenced already.
新型磷结合剂、维生素D类似物及钙敏感受体激活剂等现已陆续进入临床，并取得良好疗效。
The therapeutic effects of new type phosphate binder, vitamin D analogue and calcimimetic compound have been evidenced already.
应用推荐